Stock Analyst Note
Samsung Bio Earnings: Guidance Raised for 2026 to Top End of Range As Utilization Increases
Samsung Bio third-quarter 2026 revenue grew 19% year on year to KRW 1.49 trillion, driven by full utilization of its plants and the ramp-up of its newest Plant 5. Operating margin declined by 710 basis points, and we believe this is due to ramp up and higher labor costs.

